featured
Iruplinalkib vs Crizotinib for ALK TKI–Naïve Locally Advanced or Metastatic ALK-Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE)
J Thorac Oncol 2024 Jan 25;[EPub Ahead of Print], Y Shi, J Chen, R Yang, H Wu, Z Wang, W Yang, J Cui, Y Zhang, C Liu, Y Cheng, Y Liu, J Shan, D Wang, L Yang, C Hu, J Zhao, R Cao, B Tan, K Xu, M Si, H Li, R Mao, L Li, X Kang, L WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.